Tower Research Capital LLC TRC increased its position in shares of Core Laboratories NV (NYSE:CLB) by 412.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,723 shares of the company’s stock after buying an additional 1,387 shares during the period. Tower Research Capital LLC TRC’s holdings in Core Laboratories NV were worth $213,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the stock. MU Investments Co. Ltd. bought a new stake in shares of Core Laboratories NV during the second quarter worth $115,000. CIBC World Markets Inc. bought a new stake in shares of Core Laboratories NV during the second quarter worth $205,000. Creative Planning boosted its stake in shares of Core Laboratories NV by 19.8% in the second quarter. Creative Planning now owns 1,814 shares of the company’s stock worth $225,000 after buying an additional 300 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Core Laboratories NV during the first quarter worth $233,000. Finally, Virginia Retirement Systems ET AL bought a new stake in shares of Core Laboratories NV during the second quarter worth $235,000.
Shares of Core Laboratories NV (NYSE:CLB) opened at 108.26 on Thursday. The company has a market cap of $4.77 billion, a PE ratio of 57.43 and a beta of 1.56. Core Laboratories NV has a 52 week low of $84.50 and a 52 week high of $135.49. The company has a 50 day moving average price of $112.20 and a 200 day moving average price of $117.56.
Core Laboratories NV (NYSE:CLB) last announced its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.35. The company had revenue of $148.10 million for the quarter, compared to the consensus estimate of $146.37 million. Core Laboratories NV had a return on equity of 344.55% and a net margin of 11.81%. The firm’s revenue was down 27.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.81 EPS. On average, equities analysts expect that Core Laboratories NV will post $1.56 earnings per share for the current year.
CLB has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price objective on the stock in a research note on Wednesday, July 20th. JPMorgan Chase & Co. restated a “buy” rating on shares of Core Laboratories NV in a research note on Thursday, June 30th. KLR Group restated a “buy” rating and set a $180.00 price objective (up from $166.00) on shares of Core Laboratories NV in a research note on Monday, June 13th. Citigroup Inc. dropped their price target on shares of Core Laboratories NV from $116.00 to $110.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Credit Suisse Group AG began coverage on shares of Core Laboratories NV in a research report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price target on the stock. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $119.76.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories NV (NYSE:CLB).
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.